Search

Lithium plating can cause capacity fade and thermal runaway safety issues in lithium-ion batteries. Therefore, accurately detecting the amount of lithium plating on the surface of the battery's negative electrode is crucial for battery safety. This is especially crucial in high-energy-density applications such as battery energy storage systems or in electric vehicles (EVs). Early detection of lithium plating is crucial for evaluation of reliability and longevity. It also serves as a method for early diagnostics in practical industrial applications or infrastructure, such as EV transportation. This can enhance its impact on customers. This study validates the effectiveness of titration gas chromatography (TGC) technology in quantitatively detecting lithium plating on graphite negative electrodes in lithium-ion batteries. The results show that it can detect a minimum of 2.4 μmol of metallic lithium. Compared with the heating direct current resistance and reference electrode methods, which can be used to perform only qualitative dendrite detection, TGC has a wider range of detection. Compared with the nuclear magnetic resonance (NMR) method with higher quantitative detection accuracy, the maximum difference between the detection results of the two methods was only 7.2%, but the TGC method had lower cost and higher implementation convenience. In summary, among various dendrite detection methods, the TGC method can not only realize the effective quantitative detection of lithium plating, but also comprehensively consider its detection range, implementation convenience, cost, and detection accuracy, indicating that it is suitable for engineering applications and has the prospect of realizing large-scale quantitative detection of lithium plating in lithium-ion batteries. [ABSTRACT FROM AUTHOR]

Objective: Polymorphisms in XPG were considered to contribute to the clinical outcome of patients receiving platinum drug chemotherapy. We investigated the impact of several potential SNPs of XPG on the efficacy of platinum-based chemotherapy in NSCLC patients. Methodology: A total of 433 patients were consecutively selected between Nov. 2006 and Dec. 2007, and were followed-up up to Nov. 2011. The genotyping of six SNPs (rs2296147, rs751402, rs873601, rs4150375, rs17655 and rs2094258) were genotyped using the Taqman real-time PCR method with a 7900 HT sequence detector system. Results: Patients carrying CT+TT genotype of rs2296147 had a significantly longer median PFS (17.5 months) and OS (26.8 months) than CC genotype. Hazard ratio (HR) for PFS and OS in patients with CT+TT genotype of rs2296147 was respectively 0.73(0.51-0.97) and 0.66(0.48-0.99) when compare CC genotype, respectively. Similarly, patients with rs2094258 AG+GG genotype had a longer median progression time (18.4 months) and overall survival time (27.3 months) when compared with those with AA genotype, and HRs(95% CI) for PFS and OS were 0.44(0.34-0.78) and 0.51(0.39-0.82), respectively. Conclusions: Our study suggests rs2296147 CT+TT and rs2094258 AG+GG genotypes contribute to the better survival of NSCLC. Our study provides significant information on role of prognostic value of XPG SNPs, and detecting of XPG could be used as predictive markers toward individualizing NSCLC treatment strategies. [ABSTRACT FROM AUTHOR]